WHO endorses trials of two new Ebola vaccines amid African outbreak
Juste les faits

WHO endorses trials of two new Ebola vaccines amid African outbreak

Résumé

The World Health Organization approved clinical trials for two vaccine candidates targeting the Bundibugyo Ebola strain, while urging continued public health measures and the lifting of travel bans.

The World Health Organization announced that it will support clinical trials for two vaccine candidates designed to protect against the Bundibugyo virus, a rare Ebola variant for which no vaccine has yet been approved. The candidates are being developed through a partnership between the University of Oxford, the Serum Institute of India and Moderna, and the trial will be coordinated by the Democratic Republic of the Congo's National Institute for Biomedical Research with international assistance.

"Today WHO expert groups are recommending adding two vaccine candidates to the trial that had been developed specifically for the Bundibugyo virus," WHO Director-General Tedros Adhanom Ghebreyesus said at a press conference in Geneva.

Tedros emphasized that vaccines complement, but do not replace, established interventions such as early treatment, contact tracing, isolation, safe burials and community engagement.

The outbreak, which began in the DRC in May, has infected more than 10,000 people and caused over 5,300 deaths, with cases also reported in Kenya, Nigeria and Uganda. In response, several countries, including Ghana and the United States, imposed travel restrictions on arrivals from the DRC. The WHO chief criticized those measures.

"We call on countries that have imposed travel restrictions to lift them. Such restrictions punish countries for doing the right thing, create disincentives for transparency and harm the response," he added.

Continuez à lire — gratuitement

Créez un compte gratuit pour suivre l'actualité. Aucune carte requise.